130 related articles for article (PubMed ID: 38822544)
1. Association of GRK5 variant rs10886471 with the therapeutic effect of repaglinide in patients of type 2 diabetes mellitus in Peshawar, Pakistan.
Ijaz K; Zakiullah -; Shah H; Ali S; Raziq M; Bahadar H
Pak J Pharm Sci; 2024 Mar; 37(2(Special)):417-421. PubMed ID: 38822544
[TBL] [Abstract][Full Text] [Related]
2. A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.
Shang Z; Han F; Zhou X; Bao Z; Zhu J; Wang T; Lu Q; Du L; Li W; Lv D; Yin X
Drug Dev Res; 2018 May; 79(3):129-135. PubMed ID: 29663513
[TBL] [Abstract][Full Text] [Related]
3. GRK5 intronic (CA)n polymorphisms associated with type 2 diabetes in Chinese Hainan Island.
Xia Z; Yang T; Wang Z; Dong J; Liang C
PLoS One; 2014; 9(3):e90597. PubMed ID: 24594703
[TBL] [Abstract][Full Text] [Related]
4. A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients.
Zhou X; Chen C; Yin D; Zhao F; Bao Z; Zhao Y; Wang X; Li W; Wang T; Jin Y; Lv D; Lu Q; Yin X
Intern Med; 2019 Aug; 58(16):2341-2347. PubMed ID: 31118371
[TBL] [Abstract][Full Text] [Related]
5. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.
He YY; Zhang R; Shao XY; Hu C; Wang CR; Lu JX; Bao YQ; Jia WP; Xiang KS
Acta Pharmacol Sin; 2008 Aug; 29(8):983-9. PubMed ID: 18664331
[TBL] [Abstract][Full Text] [Related]
6. PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.
Song JF; Wang T; Zhu J; Zhou XY; Lu Q; Guo H; Zhang F; Wang Y; Li W; Wang DD; Cui YW; Lv DM; Yin XX
Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):27-32. PubMed ID: 25311380
[TBL] [Abstract][Full Text] [Related]
7. Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.
Wang T; Wang Y; Lv DM; Song JF; Lu Q; Gao X; Zhang F; Guo H; Li W; Yin XX
Pharmacotherapy; 2014 Feb; 34(2):131-9. PubMed ID: 24338736
[TBL] [Abstract][Full Text] [Related]
8. IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.
Huang Q; Yin JY; Dai XP; Pei Q; Dong M; Zhou ZG; Huang X; Yu M; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2010 Jun; 31(6):709-17. PubMed ID: 20523342
[TBL] [Abstract][Full Text] [Related]
9. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.
Huang Q; Yin JY; Dai XP; Wu J; Chen X; Deng CS; Yu M; Gong ZC; Zhou HH; Liu ZQ
Eur J Clin Pharmacol; 2010 Dec; 66(12):1207-15. PubMed ID: 20809084
[TBL] [Abstract][Full Text] [Related]
10. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
11. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
[TBL] [Abstract][Full Text] [Related]
12. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
13. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Wolffenbuttel BH; Landgraf R
Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.
Soegondo S; Subekti I; Luthariana L
Acta Med Indones; 2004; 36(3):142-7. PubMed ID: 15557683
[TBL] [Abstract][Full Text] [Related]
15. NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Sheng FF; Dai XP; Qu J; Lei GH; Lu HB; Wu J; Xu XJ; Pei Q; Dong M; Liu YZ; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2011 Aug; 38(8):550-4. PubMed ID: 21631570
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
[TBL] [Abstract][Full Text] [Related]
17. Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
Intern Med; 2016; 55(13):1697-703. PubMed ID: 27374668
[TBL] [Abstract][Full Text] [Related]
18. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
20. Metformin/Repaglinide (PrandiMet) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Jun; 51(1313):41-3. PubMed ID: 19478691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
